MBX Biosciences【MBX】銘柄情報

MBX Biosciences Inc (MBX) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

57.80

( 3.36% )

買値

41.66

売値

71.47

出来高

828,949

55.16 日の範囲 58.32

9.46 52 週間の範囲 58.50

時価総額

2.751B

前日終値

55.92

始値

56.04

時刻

最終取引時間

財務取引量

US$ 47,198,110

VWAP

56.9373

平均取引量 (3 か月)

US$ 759,339

発行済株式数

47,597,536

配当利回り

PER

-25.7

1 株当たり利益 (EPS)

-2.18

歳入

純利益

-86.61M

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is i... MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

mbxbio.com

本社

Carmel, United States

設立

2026

MBX Biosciences Inc is listed in the Healthcare sector of the ナスダック市場 with ticker MBX. The last closing price for MBX Biosciences was US$55.92. Over the last year, MBX Biosciences shares have traded in a share price range of US$ 9.46 to US$ 58.50.

MBX Biosciences currently has 47,597,536 shares in issue. The market capitalisation of MBX Biosciences is US$2.75 billion. MBX Biosciences has a price to earnings ratio (PE ratio) of -25.70.

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

MBX Biosciences Shares Fall Despite Positive One-Year Trial Results for Canvuparatide (MBX)

MBX Biosciences Inc. (NASDAQ:MBX) shares dropped 19.6% in premarket trading on Friday despite the company reporting encouraging one-year clinical...

Form 8-K - Current report

MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism

Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	8.8	17.9591836735	49	58.5	48.17	1485140	53.16247349	CS
4	27.73	92.2181576322	30.07	58.5	28	1139225	43.08920356	CS
12	26.35	83.7837837838	31.45	58.5	27.56	764763	38.31423686	CS
26	26.2	82.9113924051	31.6	58.5	26.14	685491	36.5715972	CS
52	46.15	396.137339056	11.65	58.5	9.46	813791	26.77239846	CS
156	34.8	151.304347826	23	58.5	4.8069	564512	24.13207788	CS
260	34.8	151.304347826	23	58.5	4.8069	564512	24.13207788	CS